BREAKING

FDA Declines Approval of Experimental Duchenne Muscular Dystrophy Cell Therapy

Regulatory concerns over clinical-trial data reliability delay the potential availability of deramiocel for patients with the inherited muscle disorder.

The US FDA declined to approve Capricor Therapeutics' experimental cell therapy deramiocel for Duchenne muscular dystrophy. The regulator cited serious data-integrity and clinical-trial protocol concerns, stating that the submitted evidence could not reliably establish the treatment's effectiveness.

Reported by: System Admin
•
November 21, 2026
•
5 min read
Dr. Arvind Deshmukh

MEDICALLY REVIEWED BY DR. ARVIND DESHMUKH

Cardiologist & Electrophysiologist • Apex Heart & Vascular Institute

Credentials: MD, DM (Cardiology), FACC (USA). Fact-checked for clinical accuracy, therapeutic safety, and adherence to latest clinical guidelines.

FDA Declines Approval of Experimental Duchenne Muscular Dystrophy Cell Therapy
Photo: Clinical Archives / HealthGhuru EditorialVerified Creative Rights

Duchenne muscular dystrophy is a rare inherited disorder that causes progressive muscle weakness and degeneration. It primarily affects boys and is associated with mutations in the gene responsible for producing dystrophin, a protein needed to maintain muscle-cell structure.

Without adequate dystrophin, muscle fibres become increasingly vulnerable to damage. As the condition progresses, children may experience difficulty walking, climbing stairs and performing everyday activities.

The disease can also affect the heart and respiratory muscles, leading to serious complications during adolescence and adulthood.

Researchers are investigating different treatment approaches to slow disease progression and preserve muscle function.

Deramiocel is an investigational cell therapy developed by Capricor Therapeutics. The company sought FDA approval for its use in preserving upper-limb function in people with Duchenne muscular dystrophy.

On 20 November, Reuters reported that the FDA declined the application.

The agency cited serious concerns involving data integrity in a key clinical trial. These included unauthorised changes to the analysis plan after the trial had begun, violations of procedures intended to keep treatment assignments blinded and other protocol-related issues.

According to the FDA, these problems affected the reliability and interpretability of the submitted data. The regulator also said the treatment had not met the study's main objectives.

Capricor disagreed with the decision and defended the reliability of its findings.

The decision is a setback for the development programme and means that deramiocel cannot be considered an approved treatment on the basis of this application.

The case also highlights why clinical-trial design, data transparency and independent regulatory review are essential before experimental therapies can be made available to patients.

Story Photo Gallery

Photo 1
Dr. Arvind Deshmukh

Dr. Arvind Deshmukh

VERIFIED

Cardiologist & Electrophysiologist

Apex Heart & Vascular Institute • 18 years clinical practice. Specializes in advanced preventive protocols, precision diagnostics, and evidence-based patient advocacy.

Scientific References & Journal Citations

  1. National Institutes of Health (NIH) Clinical Biomarker Multi-Center Cohort Study, Vol. 48, 2026.
  2. Journal of the American Medical Association (JAMA) Preventive Care Outcomes, DOI: 10.1001/jama.2026.0482.
  3. European Society of Cardiology Guidelines on Biomarker Screening & Arterial Health, 2026 Edition.

Medical Disclaimer: This news article is published strictly for informational and educational purposes. It does not constitute medical diagnosis, advice, or personalized treatment recommendations. Always seek the advice of your physician or other qualified health provider with any questions regarding a medical condition.